Skip to content

PharmaBXL

Active Private limited companyfounded 2022active for 3 yearsZavelput 17, 1000 BrusselsKBO/BCE: BE 0795.508.480

Lifetime

2 annual accounts with figures on one time axis
peak of €436,169 in 2024
€436,169▲ €700,674
lowest -€269,089 in 2023
€241,143▲ €510,232
peak of €382,053 in 2024
€382,053▲ 171%
€611,730▲ 42.3%
Board5 names since 2022
3 directors and 2 others
Documentsfilings and deeds
30-09-202561 days late
2024micro format
Gross margin from -€264,505 to €436,169Profit of €241,143, after a lossEquity from €140,911 to €382,053Debts from €429,957 to €611,730Investments €85,000Cash from €105,959 to €36,709

Key points

from the 2024 annual accounts

Equity

€382,053 ▲ 171%
€141,0002023€382,0002024

Equity rose in 2024 from €140,911 to €382,053.

Debts

€611,730 ▲ 42.3%
Taxes and wages
+60,046
Suppliers
+31,659
The rest
+90,067

Debts rose by €181,773 in 2024.

Investments

€85,000 5.0 times depreciation

Green is investment, beige is depreciation.

Liquidity

5.93 was 28.70 in 2023

Short-term debts rose from €19,827 to €155,936.

Board

2 joined · 3 left

2 directors joined and 3 left, the latest change on 31-03-2026. 5 are in office now.

Position in the sector

€241,143

Higher net result than 95% of companies in office administrative support. The sector median is €13,996, over 9,496 companies.

2025 accounts not filed, 113 days past the deadline

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,330 companies had the same profile as PharmaBXL has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,330 companies, not a prediction for PharmaBXL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director,
Director, since 29-12-2022
Director, since 29-12-2022
Director,
Director
  • 62,222 sharesdeed of 02-01-2023
  • 502,222 sharesdeed of 02-01-2023
  • 124,444 sharesdeed of 02-01-2023
and 3 other shareholdersBoard & ownership

Recent changes

Registered office moved from Berchem-Sainte-Agathe to Brussels The registered office moved from Koekelberglaan 1, 1082 SINT-AGATHA-BERCHEM to Zavelput 17, 1000 BRUSSEL · Board meeting of 01-06-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0795508480
New managing director appointed, resigned · and act as permanent representatives · Board meeting of 13-02-2026 · Gazette deed
1 director appointed, 2 resignations 110,208 new shares · 5,402,453 new shares · and resign · General meeting of 30-12-2025 · Gazette deed
All 12 events

Comparable companies

same main activity, similar in size and age
Company
PharmaBXL Brussels €1.0m €436,169 38.4% -
DANLEY Antwerp €0.9m €394,802 74.0% -
G-ausa-R Maldegem €0.8m €417,758 73.5% -
P&VB Consulting Antwerp €0.8m €488,522 83.0% -
Expatgate Lokeren €0.8m €369,098 66.9% -
FIDEVINC Lasne €1.1m €572,630 77.4% -
K & E Consult Londerzeel €0.8m €423,551 58.3% -

These companies have the same main activity as PharmaBXL: other business support services (NACE 82990). They are comparable in size and age: total assets between €763,000 and €1.1m, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 29-12-2022Normal situation
Activity
Other business support servicesNACE 82990and 3 others
Joint committee
313Pharmacies and pricing offices · annual accounts 2024
Establishment unit
2.340.231.7971000 Brussels, registered on 29-12-2022
Financial year end
31 December
Peppol
Reachable since 06-04-2026
Company details

Annual accounts 2024

≈ €650,000estimated
€993,783▲ 74.1%
Filing
Filed on 30-09-2025
Financials

Insights on PharmaBXL

The 2024 annual accounts show equity of €382,053 and a net result of €241,143, with €242,565 of non-recurring income. Its solvency ranks better than 40% of 9,497 sector peers (NACE 82) in financial year 2024.

The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PharmaBXL

What is the company number of PharmaBXL?
The company number of PharmaBXL is 0795.508.480. The VAT number is the same number with BE in front: BE 0795.508.480.
Where is PharmaBXL based?
The registered office is at Zavelput 17, 1000 Brussels.Company details
What does PharmaBXL do?
According to the KBO register, the main activity is other business support services (NACE 82990).
What is the legal form of PharmaBXL?
PharmaBXL is a private limited company (BV).
When was PharmaBXL founded?
PharmaBXL was founded on 29-12-2022.
Is PharmaBXL still active?
Yes, PharmaBXL is an active enterprise in the KBO register.
How many employees does PharmaBXL have?
PharmaBXL had an average of 0.1 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
Which joint committee does PharmaBXL fall under?
In its 2024 annual accounts, PharmaBXL states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of PharmaBXL?
The turnover in financial year 2024 is about €650,000. This figure is estimated from the gross margin of €436,169 and 33 comparable companies (NACE 82990). It probably lies between €540,000 and €920,000.
Is PharmaBXL profitable?
In financial year 2024, PharmaBXL made a profit of €241,143.
Where can I find the annual accounts of PharmaBXL?
PharmaBXL filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
When are the next annual accounts of PharmaBXL due?
PharmaBXL had to file the annual accounts for financial year 2025 by 31-07-2026. On 21-11-2026 they are not filed yet, 113 days past the deadline.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.